9:04 AM
 | 
Mar 26, 2018
 |  BC Extra  |  Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control over a protein's expression than traditional genetic or pharmacological approaches (see BioCentury Innovations, March 26).
Bradner is president of the Novartis Institutes for BioMedical Research (NIBR). Gray...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >